Dapagliflozin ở bệnh nhân tiểu đường loại 2 nhận liều insulin cao: hiệu quả và an toàn trong 2 năm
Tóm tắt
Từ khóa
Tài liệu tham khảo
Verbeke G, 2000, Linear Mixed Models for Longitudinal Data
Davis SJ. Effects of severe hypoglycemia on primary outcomes death and myocardial infarction in VADT. New analyses from ACCORD and VADT [Webcast]. Proceedings of the American Diabetes Association's 69th Scientific Sessions 5–9 June 2009 New Orleans USA. Available from URL:http://professional.diabetes.org/Presentations_Search.aspx. Accessed 15 November 2012.
Rohwedder K, 2011, Dapagliflozin, a Sodium‐Glucose Cotransporter 2 Inhibitor, Has a Low Propensity To Cause Hypoglycemia in Patients with Type 2 Diabetes, Diabetes, 60, A286
Ptaszynska A, 2012, Safety of dapagliflozin in Clinical Trials for T2DM [Abstract 1011‐P], Diabetes, 61, A258
Cefalu WT Leiter LA Yoon K‐H et al. Canagliflozin (CANA) Demonstrates Durable Glycemic Improvements Over 104 Weeks versus Glimepiride (GLIM) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) [Abstract 65‐LB]. 73rd Scientific Sessions of the American Diabetes Association June 21–25 2013 Chicago IL USA. Available from URL:http://diabetes.diabetesjournals.org/content/suppl/2013/06/21/62.Supplement_1.DC1/2013‐Late‐Breaking‐Abstracts.pdf. Accessed 26 June 2013.
AstraZeneca and Bristol‐Myers Squibb. Dapagliflozin Summary of Product Characteristics (SmPC). 2013. Available from URL:http://www.forxiga.eu/Forxiga%20Summary%20of%20Product%20Characteristics_SmPC_.pdf. Accessed 26 June 2013.